Advertisement

Topics

ASCO 2017: Abiraterone delays metastatic prostate cancer growth by 18 months, extends survival

08:30 EDT 3 Jun 2017 | ecancermedicalscience

Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 men, abiraterone also more than...

Original Article: ASCO 2017: Abiraterone delays metastatic prostate cancer growth by 18 months, extends survival

NEXT ARTICLE

More From BioPortfolio on "ASCO 2017: Abiraterone delays metastatic prostate cancer growth by 18 months, extends survival"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...